THE DOCTORS LABORATORY LIMITED
Get an alert when THE DOCTORS LABORATORY LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2027-03-31 (in 10mo)
Last filed for 2025-06-30
Confirmation statement due
2026-09-15 (in 4mo)
Last made up 2025-09-01
Watchouts
None on the register
Cash
£8M
-21.3% vs 2024
Net assets
£401M
+17.2% vs 2024
Employees
860
+4% vs 2024
Profit before tax
£110M
+66.2% vs 2024
Name history
Renamed 1 time since incorporation
- THE DOCTORS LABORATORY LIMITED 1988-02-03 → present
- SPURDRIVE PUBLIC LIMITED COMPANY 1987-12-03 → 1988-02-03
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2025-06-30
| Metric | Trend | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Turnover | £147,871,000 | £152,784,000 | |
| Operating profit | £26,403,000 | £30,187,000 | |
| Profit before tax | £65,905,000 | £109,531,000 | |
| Net profit | £52,133,000 | £102,226,000 | |
| Cash | £9,929,000 | £7,812,000 | |
| Total assets less current liabilities | £553,899,000 | £621,259,000 | |
| Net assets | £341,747,000 | £400,523,000 | |
| Equity | £341,747,000 | £400,523,000 | |
| Average employees | 827 | 860 | |
| Wages | £30,089,000 | £32,810,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating margin | 17.9% | 19.8% | |
| Net margin | 35.3% | 66.9% | |
| Return on capital employed | 4.8% | 4.9% | |
| Gearing (liabilities / total assets) | 44.5% | 39.0% | |
| Current ratio | 1.38x | 3.36x | |
| Interest cover | 5.21x | 6.77x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company is in a profitable position, has sufficient working capital and a number of long term contracts which gives a positive trading outlook. The directors therefore believe that it is appropriate to prepare the financial statements on a going concern basis.”
Group structure
- THE DOCTORS LABORATORY LIMITED · parent
- Health Services Laboratories LLP 51%
- LABex Facilities LLP 99.9%
- LABex Analytics LLP 99.9%
- HSL Pathology LLP 51%
- HSL (Nominee) Limited 51%
- HSL (FM) LLP 51%
- HSL (Analytics) LLP 51%
- Medisoutien Holding SA 100%
- Sonic Suisse Labs SA 100%
- Dianalabs SA 99.77%
- Polyanalytic SA 90%
- Dianalabs Valais SA 100%
- MCL Medizinische Laboratorien AG 100%
- Genesupport SA 100%
- Dianalabs Mittelland AG 100%
- Ortho-Analytic AG 100%
- Proxilab analyses medicales SA 100%
- CPMA SA 94.4%
- Fertas SA 94.4%
- Aurigen SA 100%
- Sonic Suisse SSD SA 100%
- LABORATOIRES BVV S.A. 100%
- Bioanalytica AG 100%
- Ecobion SA 100%
- Bioexam AG 100%
- Bioanalytica Aareland AG 100%
- Medi-Centre SA 65%
- Medizinische Laboratorien Dr. Toggweiler AG 100%
- Siloah AG 10%
- TORRE Schweiz AG Ganzheitliche Pharmazie 6.64%
- DIANAPATH SA 100%
- Medaxo Praxen AG 8.63%
- RARECELLS, INC 0.57%
- Medigenome SA 60%
- Medidata AG 0.72%
- Praxisgemeinschaft am Lindenberg AG 10%
- Medizinisches Zentrum Hochdorf AG 10%
- Praxisgemeinschaft Oberhof AG 10%
- Praxisgemeinschaft Erlosen AG 10%
- Genossenschaft Gesundheitszentrum Entlebuch
- Medipark Capital AG 37.5%
- FLONMED SA 100%
- Chinon Holding SA 96.7%
- Imagerie du Flon SA 78.85%
- MedUp SA 34%
- Sanador St. Jakob AG 10%
- Hausarztpraxis Muttenz AG 10%
- docstation Emmen AG 14.77%
- MEDISYN SA 100%
- Dr Risch AG 100%
- one-provide ag 100%
- Institut Arnaboldi AG 100%
- Bakteriologisches Institut Olten BIO AG 30%
- Dr. Risch AG 100%
- Dr. Risch arc lémanique SA 100%
- Dr. Risch Holding AG 100%
- Dr. Risch Ostschweiz AG 100%
- Dr. Risch Services AG 100%
- Dr. Risch Shared Services AG 100%
- Dr. Risch Ticino SA 100%
- Delivery Glider AG 10.62%
- PATHOdiagnostics AG, Institut fur Pathologie 25%
- INTLAB AG 11.1%
- CALCISCON AG 1.26%
- XATENA AG 2.82%
- Akademie-Dialog Santè AG 2%
- Mobile Health AG 2.8%
- PARTUA AG 39%
- poolprax AG 8.58%
- emedSwiss SA 2.4%
- Switzerland Innovation Park Ost AG 3%
- Haus der Medizin AG 12.5%
- Genossenschaft Ärztehaus Reusslistrasse
- Hausarztzentrum Altstadt AG 8.45%
- Medipark Swiss AG 37.5%
- medica Ärztebedarf AG 100%
- MEDICA Medizinische Laboratorien AG 100%
- Mikrogen Labor GmbH 100%
- selftesting.ch GmbH 100%
- Serolife GmbH 100%
- Pathologie Dr. Noll AG 100%
- Aerztelabor Dr. Kurt Furrer GmbH 100%
- Labor Prof. Krech und Partner GmbH 100%
- Institut Virion GmbH 100%
- Medizinisches Institut R. Rondez GmbH 100%
- Labormed Medizinische Laboratorien GmbH 100%
- Virion Labordiagnostik GmbH 100%
- LB Medizinisches Labor Solothurn GmbH 100%
- Pathologie Institut Enge AG 100%
- PDS MEDICAL SA 28%
- LabCare SA 51%
- Medzentrum Emmen AG 10%
- docstation Schweiz AG 16.5%
- med:compact AG 100%
Significant events
- “On 19 November 2025, the Company acquired the entire share capital of Cellular Pathology Services Limited for consideration of £12,505,000 including a freehold property.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
13 active · 13 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ALEXANDER, Paul Joseph | Secretary | 2003-07-29 | — | Australian |
| SYMONDS, Stephen Daniel | Secretary | 2024-08-07 | — | — |
| BYRNE, David Anthony | Director | 1998-03-01 | Nov 1959 | British |
| HERRIMAN, Timothy | Director | 2018-08-01 | Jul 1977 | British |
| LEVETT, Lisa, Dr | Director | 2018-08-01 | Apr 1972 | British |
| LIEBMANN, Rachael, Dr | Director | 2020-07-17 | Jul 1966 | British |
| MADDEN, Brian | Director | 2021-03-01 | Sep 1982 | Irish |
| MATTHEWS, John Robert | Director | 2018-08-01 | Feb 1972 | British |
| NEWCOMBE, James Pacey, Dr | Director | 2025-11-20 | Jan 1979 | Australian |
| PRUDO-CHLEBOSZ, Raymond, Dr | Director | — | Nov 1944 | Canadian |
| SYMONDS, Stephen Daniel | Director | 2024-08-07 | Sep 1974 | British |
| WILKINSON, Annette Joan | Director | 1999-07-01 | Jun 1957 | British |
| WILKS, Christopher David | Director | 2002-04-17 | Sep 1958 | Australian |
Show 13 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| AMIES, Thomas George Timothy | Secretary | 2014-04-02 | 2022-04-01 |
| BYRNE, David Anthony | Secretary | 1998-02-01 | 2014-04-02 |
| FENTON, Lawrence Stanley | Secretary | — | 1998-02-01 |
| READ, Nicholas | Secretary | 2022-04-01 | 2024-07-31 |
| AMIES, Thomas George Timothy | Director | 2014-03-10 | 2022-04-01 |
| FENTON, Lawrence Stanley | Director | — | 1998-02-01 |
| GOLDSCHMIDT, Colin Stephen, Dr | Director | 2002-04-17 | 2025-11-20 |
| JOYCE, Robert | Director | 2000-02-01 | 2012-04-10 |
| NEEP, David | Director | 1997-10-20 | 2002-04-10 |
| READ, Nicholas | Director | 2022-04-01 | 2024-07-31 |
| SOLINSKI, Andrew | Director | 1999-07-01 | 2002-03-09 |
| UNGAR, Stuart Charles | Director | 2007-04-04 | 2007-09-30 |
| UNGAR, Stuart Charles | Director | — | 2007-04-04 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Sonic Healthcare Holding Company | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 227 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-12 | AA | accounts | Accounts with accounts type full | |
| 2025-12-11 | AP01 | officers | Appoint person director company with name date | |
| 2025-12-03 | TM01 | officers | Termination director company with name termination date | |
| 2025-09-11 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-04-04 | AA | accounts | Accounts with accounts type full | |
| 2024-09-04 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-08-07 | AP03 | officers | Appoint person secretary company with name date | |
| 2024-08-07 | AP01 | officers | Appoint person director company with name date | |
| 2024-08-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-08-01 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-06-12 | DISS40 | gazette | Gazette filings brought up to date | |
| 2024-06-11 | AA | accounts | Accounts with accounts type full | |
| 2024-05-28 | GAZ1 | gazette | Gazette notice compulsory | |
| 2024-04-10 | SH01 | capital | Capital allotment shares | |
| 2023-09-01 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-08-25 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2023-07-20 | AAMD | accounts | Accounts amended with accounts type full | |
| 2023-07-13 | AA | accounts | Accounts with accounts type full | |
| 2023-02-06 | SH01 | capital | Capital allotment shares | |
| 2022-09-15 | CS01 | confirmation-statement | Confirmation statement with updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2024 → FY2025 · period ending 2025-06-30 vs 2024-06-30
-
Turnover
+3.3%
£147,871,000 £152,784,000
-
Cash
-21.3%
£9,929,000 £7,812,000
-
Net assets
+17.2%
£341,747,000 £400,523,000
-
Employees
+4%
827 860
-
Operating profit
+14.3%
£26,403,000 £30,187,000
-
Profit before tax
+66.2%
£65,905,000 £109,531,000
-
Wages
+9%
£30,089,000 £32,810,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers